Search Results - "Telivala, Bijoy"

A Rare Case of Iron Overload in Hereditary Spherocytosis: A Case Report by Bui, Audrey, Shah, Avani P, Chae, Min Y, Popard, Peyton, Telivala, Bijoy

“…Hereditary spherocytosis (HS) is a hereditary hematologic disorder characterized by fragile spherical red blood cells that are susceptible to hemolysis. HS…”
Get full text

Remote patient monitoring (RPM) through smartphone application in community oncology practice by Kuthiala, Rayna, Telivala, Bijoy Pankaj, Karawadia, Tejas

“…e18828 Background: Patients with cancer receiving treatment can have symptoms related to their disease or treatment. Early recognition and appropriate…”
Get full text

Electronic patient-reported outcomes in a cohort of patients with lung cancer treated in the community with shorter versus longer course PD1/PDL1 therapy by Kolodziej, Michael A., Kwiatkowsky, Lavi, Travis, Patrick M., Blau, Sibel, Kuthiala, Sejal, Telivala, Bijoy Pankaj, Calkins, Geoffrey, Parrinello, Christina

“…e18810 Background: PD1/PDL1 (IO) therapy has been extensively studied as monotherapy and in combination with other IO therapy, chemotherapy and targeted…”
Get full text

Time on treatment is prolonged in patients utilizing an ePRO based digital symptom monitoring platform in the community setting by Parrinello, Christina, Calkins, Geoffrey, Kwiatkowsky, Lavi, Schaefer, Eric S., Beck, J. Thaddeus, Ellis, Amy R., Blau, Sibel, Telivala, Bijoy Pankaj, Kolodziej, Michael A.

“…1528 Background: Earlier and more effective management of cancer-related symptoms and treatment-related toxicities might improve the survival of patients…”
Get full text

Abstract P1-18-25: Real-world quality of life (QoL) in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), advanced breast cancer (ABC) treated with palbociclib: A patient-reported outcome (PRO) analysis from POLARIS by Karuturi, Meghan S., Rocque, Gabrielle B., Cappelleri, Joseph C., Blum, Joanne L., McCune, Steven L., Telivala, Bijoy, Kurian, Sobha, Anderson, Daniel M., Tsai, Michaela, Pluard, Timothy, Migas, John, Wang, Yao, Montelongo, Monica Z., Tripathy, Debu

“…Background: POLARIS is an ongoing, prospective, real-world, noninterventional, multicenter study in patients with HR+/HER2- ABC receiving palbociclib in the…”
Get full text

Abstract P1-18-05: Early changes in circulating tumor DNA and its effect on clinical outcomes in patients with advanced breast cancer receiving the CDK4/6 inhibitor palbociclib: Genotyping results from POLARIS by Tripathy, Debu, Zhang, Zhe, Blum, Joanne L., Karuturi, Meghan S., McCune, Steven L., Telivala, Bijoy, Lakhanpal, Shailendra, Patel, Kamal, Frank, Richard C., Lu, Kit, Deshpande, Chetan, Wang, Yao, Liu, Yuan, Bardia, Aditya

“…Background: POLARIS is a prospective, real-world study of palbociclib in patients with hormone receptor-positive (HR+)/human epidermal growth factor receptor…”
Get full text

Abstract PD10-03: Quality of life in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer treated with palbociclib in real-world practice settings by Rocque, Gabrielle, Blum, Joanne L, Montero, Aldemar, Nakhoul, Ibrahim, Kurian, Sobha, Frank, Richard C, Telivala, Bijoy, Ajmera, Mayank, Coblentz, David, Cappelleri, Joseph C, Wang, Yao, Tripathy, Debu

“…Background: Palbociclib in combination with endocrine therapy (ie, an aromatase inhibitor [AI] or fulvestrant) is a current standard of care for patients with…”
Get full text

Luminespib plus pemetrexed in patients with non-squamous non-small cell lung cancer by Noor, Zorawar S., Goldman, Jonathan W., Lawler, William E., Telivala, Bijoy, Braiteh, Fadi, DiCarlo, Brian A., Kennedy, Kathleen, Adams, Brad, Wang, Xiaoyan, Jones, Benjamin, Slamon, Dennis J., Garon, Edward B.

“…•The maximum tolerated dose of luminespib is 55 mg/m2 when given in combination with pemetrexed at 500 mg/m2.•The objective response rate was 14% amongst…”
Get full text

What is the benefit from second- and third-line (2L and 3L) therapy for extensive disease small cell lung cancer (ED-SCLC)? A prospective study of patterns, discontinuation, and survival in US community practices by Richards, Donald A., Hussein, Maen A., McCune, Steven L., Ulrich, Brian Kent, Telivala, Bijoy PanKaj, Monte, Marc, Danese, Mark D., Gleeson, Michelle L., Lubeck, Deborah P., Sanzari, Jenine, Penrod, John R., Yuan, Yong, Abraham, Pranav, Korytowsky, Beata, Schwartzberg, Lee Steven

“…Abstract only…”
Get full text

Measures of functional status in older patients treated with palbociclib for advanced breast cancer by Karuturi, Meghan S., Cappelleri, Joseph C., Blum, Joanne L., Patel, Kamal, Telivala, Bijoy, McCune, Steven, Cuevas, Juan Daniel, Lakhanpal, Shailendra, Montelongo, Monica Z., Wang, Yao, Tripathy, Debu, Rocque, Gabrielle B.

“…Limited data are available on the effects of treatment for advanced breast cancer (ABC) in older patients because this population has limited enrollment in…”
Get full text